Danicopan: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), G-BA (Germany) and NICE (England), among others, recommended or restricted danicopan, while AOTMIT (Poland), HAS (France) and HIRA (South Korea) did not recommend it.
Every record falls within a 1.5-year window, 17 Apr 2024 to 7 Oct 2025 — a compressed review cycle.
CIPM (Spain) changed its position: not recommended on 18 Dec 2024, recommended by 26 Mar 2025, after a resubmission.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 12 of 12 records date from 2023 or later.
3 distinct indication wordings are recorded for danicopan by the agencies that label one in English (AWMSG, NICE and SMC).
CHUIKYO (Japan) was first to assess danicopan, on 17 Apr 2024; AIFA (Italy) did not open a file until 7 Oct 2025 — a moderate spread of 1.5 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 12 dated records fall in 2024 alone.
CIPM (Spain) is the only agency to have returned to danicopan, recording 2 separate entries.
11 of the 18 agencies in this archive hold a record for danicopan.
The full ledger for danicopan reads 4 recommended, 4 not recommended, 2 restricted and 1 no benefit, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| ZIN (Netherlands) | 10 Sep 2025 | Advies - vergoed danicopan (Voydeya®) voor de behandeling van paroxismale nachtelijke hemoglobinurie | reimbursed | source |
| AOTMIT (Poland) | 2 Apr 2025 | programu lekowego B.96 „Leczenie chorych z nocną napadową hemoglobinurią (PNH) (ICD-10 D59.5) | not recommended | source |
| CIPM (Spain) | 26 Mar 2025 | Indicación terapéutica autorizada: Voydeya está indicado de forma complementaria a ravulizumab o eculizumab para el trat… | financed by the SNS, on appeal · art. 92 a, c | source |
| HIRA (South Korea) | 6 Mar 2025 | 발작성 야간 혈색소뇨증 환자에서 혈관외용혈 증상이나 징후가 있는 경우 부가요법 | not reimbursed | source |
| SMC (Scotland) | 13 Jan 2025 | As an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. | accepted (restricted) | source |
7 further decisions for danicopan, across 7 agencies, are not shown here. They include the most recent record on file, 7 Oct 2025 from AIFA (Italy); its outcome is in the subscriber dataset. They link to 7 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 12 decisions for danicopan from 11 agencies, 2024 to 2025. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.